hims & hers
Dr. Stahl is the Director of Male Reproductive and Sexual Medicine at New York-Presbyterian Hospital/Columbia University Irving Medical Center and Associate Professor of Urology at the Columbia University Vagelos College of Physicians and Surgeons. He completed his undergraduate studies at Cornell University, and subsequently attended medical school and completed his urology residency at New York Presbyterian-Hospital/Weill Cornell Medical College in New York City. Following residency, he completed two years of fellowship training in male reproductive medicine, and microsurgery at the Center for Reproductive Medicine and Microsurgery at Weill Cornell. He received additional training during fellowship in male sexual medicine and penile reconstructive surgery at Memorial Sloan-Kettering Cancer Center.
Dr. Stahl is a recognized leader in the medical and surgical treatment of sexual disorders that affect men. He has published more than 45 articles in peer-reviewed medical literature, serves as a reviewer for several major academic journals, and is a member of numerous professional associations including the American Urological Association and the Sexual Medicine Society of North America.
This person is not in any offices
hims & hers
36 followers
Hims & Hers Health, Inc. (better known as Hims & Hers) is a multi-specialty telehealth platform building a virtual front door to the healthcare system. Hims & Hers connects consumers to licensed healthcare professionals, enabling people to access high-quality medical care—from wherever is most convenient—for numerous conditions related to primary care, mental health, sexual health, skincare, and more. Launched in November 2017, the platform also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers’ mission is to make it easier for all Americans to access affordable care and treatment for conditions that impact their daily lives. In January 2021, the company was listed on the NYSE at an initial valuation of $1.6 billion and is traded under the ticker symbol “HIMS”.